Researchers are solely responsible for the appropriate reconstitution of all OROS research compounds
Commercial/vendor material
And while human trials are still limited, the risks FDA cites are risks of the supply chain , not the science
In rodent models, BPC-157 demonstrated a wide therapeutic index with no observed hepatotoxicity, nephrotoxicity, or neurotoxicity across multiple dosing regimens. Sikiric et al., Regenerative Pharmacology Reported Side Effects (Rare) While side effects are rare, some users report: Peptides like BPC-157 generally exhibit low immunogenicity and low systemic toxicity, though user-specific variables such as injection technique or gut sensitivity may influence short-term side effects. [Clinical Peptide Society Review, 2021] Is BPC-157 Safe for Long-Term Use
On the other hand, with IBD-current biologic therapies limited to blocking tumor necrosis factor alpha some theoretical/practical inconsistencies appear